Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70


Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.

Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S.

Clin Cancer Res. 2019 Sep 20. doi: 10.1158/1078-0432.CCR-19-0955. [Epub ahead of print]


Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma.

Chaddad A, Daniel P, Sabri S, Desrosiers C, Abdulkarim B.

Cancers (Basel). 2019 Aug 10;11(8). pii: E1148. doi: 10.3390/cancers11081148.


Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation.

Chaddad A, Kucharczyk MJ, Daniel P, Sabri S, Jean-Claude BJ, Niazi T, Abdulkarim B.

Front Oncol. 2019 May 21;9:374. doi: 10.3389/fonc.2019.00374. eCollection 2019. Review.


An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, Basik M, Koromilas AE.

Nat Commun. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.


Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.

Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS.

Front Oncol. 2019 Feb 4;9:41. doi: 10.3389/fonc.2019.00041. eCollection 2019. Review.


Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM.

Breast Cancer Res. 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1.


Novel Radiomic Features Based on Joint Intensity Matrices for Predicting Glioblastoma Patient Survival Time.

Chaddad A, Daniel P, Desrosiers C, Toews M, Abdulkarim B.

IEEE J Biomed Health Inform. 2019 Mar;23(2):795-804. doi: 10.1109/JBHI.2018.2825027. Epub 2018 Apr 9.


Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.

Chaddad A, Sabri S, Niazi T, Abdulkarim B.

Med Biol Eng Comput. 2018 Dec;56(12):2287-2300. doi: 10.1007/s11517-018-1858-4. Epub 2018 Jun 19.


Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer.

Oweida A, Sabri S, Al-Rabea A, Ebrahimi M, Ruo R, Fraser R, Seuntjens J, Abdulkarim B.

Oncotarget. 2017 Nov 28;9(2):1630-1640. doi: 10.18632/oncotarget.22727. eCollection 2018 Jan 5.


Prognostic factors for progression in atypical meningioma.

Shakir SI, Souhami L, Petrecca K, Mansure JJ, Singh K, Panet-Raymond V, Shenouda G, Al-Odaini AA, Abdulkarim B, Guiot MC.

J Neurosurg. 2018 Nov 1;129(5):1240-1248. doi: 10.3171/2017.6.JNS17120.


Predicting survival time of lung cancer patients using radiomic analysis.

Chaddad A, Desrosiers C, Toews M, Abdulkarim B.

Oncotarget. 2017 Nov 1;8(61):104393-104407. doi: 10.18632/oncotarget.22251. eCollection 2017 Nov 28.


CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide.

Kaur S, Ramdzan ZM, Guiot MC, Li L, Leduy L, Ramotar D, Sabri S, Abdulkarim B, Nepveu A.

Neuro Oncol. 2018 Mar 27;20(4):484-493. doi: 10.1093/neuonc/nox178.


Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.

Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, Abdulkarim B, Nakano I, Rak J.

Neuro Oncol. 2018 Jan 22;20(2):236-248. doi: 10.1093/neuonc/nox142.


Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.

Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):1021-1028. doi: 10.1016/j.ijrobp.2017.07.012. Epub 2017 Jul 14.


High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.

Gupta N, Jung K, Wu C, Alshareef A, Alqahtani H, Damaraju S, Mackey JR, Ghosh S, Sabri S, Abdulkarim BS, Bigras G, Lai R.

Oncotarget. 2017 Apr 25;8(17):28101-28115. doi: 10.18632/oncotarget.15891.


Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.

Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot MC, Owen S, Panet-Raymond V, Souhami L, Abdulkarim BS.

J Neurooncol. 2017 May;132(3):419-426. doi: 10.1007/s11060-017-2383-2. Epub 2017 Apr 3.


Guanabenz Sensitizes Pancreatic β Cells to Lipotoxic Endoplasmic Reticulum Stress and Apoptosis.

Abdulkarim B, Hernangomez M, Igoillo-Esteve M, Cunha DA, Marselli L, Marchetti P, Ladriere L, Cnop M.

Endocrinology. 2017 Jun 1;158(6):1659-1670. doi: 10.1210/en.2016-1773.


A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.

Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):487-494. doi: 10.1016/j.ijrobp.2016.11.006. Epub 2016 Nov 15.


Ablative versus fractionated radiation therapy: a controversial role in cancer invasion and metastasis.

Oweida A, Abdulkarim B.

Oncogene. 2016 Nov 10;35(45):5928-5929. doi: 10.1038/onc.2016.130. Epub 2016 Apr 25. No abstract available.


Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Oweida A, Sharifi Z, Halabi H, Xu Y, Sabri S, Abdulkarim B.

Cancer Biol Ther. 2016 Apr 2;17(4):390-9. doi: 10.1080/15384047.2016.1139241.


A Missense Mutation in PPP1R15B Causes a Syndrome Including Diabetes, Short Stature, and Microcephaly.

Abdulkarim B, Nicolino M, Igoillo-Esteve M, Daures M, Romero S, Philippi A, Senée V, Lopes M, Cunha DA, Harding HP, Derbois C, Bendelac N, Hattersley AT, Eizirik DL, Ron D, Cnop M, Julier C.

Diabetes. 2015 Nov;64(11):3951-62. doi: 10.2337/db15-0477. Epub 2015 Jul 9.


Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients.

Jung K, Sabri S, Hanson J, Xu Y, Wang YW, Lai R, Abdulkarim BS.

Cancer Biol Ther. 2015;16(9):1281-8. doi: 10.1080/15384047.2015.1056945.


Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.

Azoulay M, Santos F, Souhami L, Panet-Raymond V, Petrecca K, Owen S, Guiot MC, Patyka M, Sabri S, Shenouda G, Abdulkarim B.

Radiat Oncol. 2015 Apr 26;10:106. doi: 10.1186/s13014-015-0396-6.


Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter.

Jung K, Gupta N, Wang P, Lewis JT, Gopal K, Wu F, Ye X, Alshareef A, Abdulkarim BS, Douglas DN, Kneteman NM, Lai R.

Oncotarget. 2015 Apr 30;6(12):10366-73.


Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia.

Igoillo-Esteve M, Gurgul-Convey E, Hu A, Romagueira Bichara Dos Santos L, Abdulkarim B, Chintawar S, Marselli L, Marchetti P, Jonas JC, Eizirik DL, Pandolfo M, Cnop M.

Hum Mol Genet. 2015 Apr 15;24(8):2274-86. doi: 10.1093/hmg/ddu745. Epub 2014 Dec 30.


Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

Jung K, Wang P, Gupta N, Gopal K, Wu F, Ye X, Alshareef A, Bigras G, McMullen TP, Abdulkarim BS, Lai R.

Breast Cancer Res. 2014 Nov 8;16(6):470. doi: 10.1186/s13058-014-0470-2.


YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.

Jung K, Wu F, Wang P, Ye X, Abdulkarim BS, Lai R.

BMC Cancer. 2014 May 9;14:328. doi: 10.1186/1471-2407-14-328.


Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Lecavalier-Barsoum M, Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2014 May 15;(5):CD007104. doi: 10.1002/14651858.CD007104.pub2. Review.


RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).

Ezzeldin M, Borrego-Diaz E, Taha M, Esfandyari T, Wise AL, Peng W, Rouyanian A, Asvadi Kermani A, Soleimani M, Patrad E, Lialyte K, Wang K, Williamson S, Abdulkarim B, Olyaee M, Farassati F.

Mol Oncol. 2014 Jul;8(5):1043-53. doi: 10.1016/j.molonc.2014.03.020. Epub 2014 Apr 13.


A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life.

Boychak A, Bauman G, Fisher B, Abdulkarim B, Amanie J, Fulton D, Murtha A, Patel S, Urtasun R, Ghosh S, Roa WH.

Am J Clin Oncol. 2016 Apr;39(2):160-6. doi: 10.1097/COC.0000000000000034.


RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate.

Cnop M, Abdulkarim B, Bottu G, Cunha DA, Igoillo-Esteve M, Masini M, Turatsinze JV, Griebel T, Villate O, Santin I, Bugliani M, Ladriere L, Marselli L, McCarthy MI, Marchetti P, Sammeth M, Eizirik DL.

Diabetes. 2014 Jun;63(6):1978-93. doi: 10.2337/db13-1383. Epub 2013 Dec 30.


tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans.

Igoillo-Esteve M, Genin A, Lambert N, Désir J, Pirson I, Abdulkarim B, Simonis N, Drielsma A, Marselli L, Marchetti P, Vanderhaeghen P, Eizirik DL, Wuyts W, Julier C, Chakera AJ, Ellard S, Hattersley AT, Abramowicz M, Cnop M.

PLoS Genet. 2013 Oct;9(10):e1003888. doi: 10.1371/journal.pgen.1003888. Epub 2013 Oct 31.


Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation.

Hwang S, Moon DB, Ahn CS, Kim KH, Ha TY, Song GW, Jung DH, Park GC, Lee HC, Lee YS, Chung YH, Abdulkarim BA, Lee SG.

Transplant Proc. 2013 Oct;45(8):3076-84. doi: 10.1016/j.transproceed.2013.08.068.


Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.

Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B.

PLoS One. 2013 Aug 26;8(8):e71987. doi: 10.1371/journal.pone.0071987. eCollection 2013.


Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.


Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.

Zeng Z, Ren J, O'Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA.

BMC Cancer. 2012 Dec 7;12:584. doi: 10.1186/1471-2407-12-584.


O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.

Chahal M, Abdulkarim B, Xu Y, Guiot MC, Easaw JC, Stifani N, Sabri S.

Mol Cancer Ther. 2012 Nov;11(11):2440-50. doi: 10.1158/1535-7163.MCT-11-0977. Epub 2012 Sep 17.


Skin-sparing helical tomotherapy vs 3D-conformal radiotherapy for adjuvant breast radiotherapy: in vivo skin dosimetry study.

Capelle L, Warkentin H, Mackenzie M, Joseph K, Gabos Z, Pervez N, Tankel K, Chafe S, Amanie J, Ghosh S, Parliament M, Abdulkarim B.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e583-90. doi: 10.1016/j.ijrobp.2012.01.086. Epub 2012 May 12.


Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy.

Quon H, Brunet B, Alexander A, Murtha A, Abdulkarim B, Fulton D, Smerdely M, Johnson M, Urtasun R, Patel S, Ghosh S, Roa W.

Anticancer Res. 2011 Oct;31(10):3559-65.


Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking.

Wu C, Gilroy R, Taylor R, Olyaee M, Abdulkarim B, Forster J, O'Neil M, Damjanov I, Wan YJ.

Hepatology. 2011 Dec;54(6):1966-74. doi: 10.1002/hep.24645.


Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma.

Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P.

Mol Oncol. 2011 Oct;5(5):410-25. doi: 10.1016/j.molonc.2011.07.005. Epub 2011 Jul 28.


Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S.

J Clin Oncol. 2011 Jul 20;29(21):2852-8. doi: 10.1200/JCO.2010.33.4714. Epub 2011 Jun 13.


Blood group A isoagglutinins in A(2) → O simultaneous liver/kidney transplantation may not influence kidney function.

Bryan CF, Abdulkarim B, Nawabi A, Stewart D, Yarlagadda SG.

Am J Transplant. 2011 Jul;11(7):1527-30. doi: 10.1111/j.1600-6143.2011.03575.x. Epub 2011 Jun 10.


The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.

Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.

Breast Cancer Res Treat. 2010 Nov;124(1):187-94. doi: 10.1007/s10549-010-1135-1. Epub 2010 Sep 3.


Metabolic modulation of glioblastoma with dichloroacetate.

Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC.

Sci Transl Med. 2010 May 12;2(31):31ra34. doi: 10.1126/scitranslmed.3000677.


A new role for the virtual crossmatch in kidney allograft reuse.

Bryan CF, Abdulkarim B, Forster J, Nelson PW, Diederich D, Murillo D, Markham L.

Transplantation. 2010 Mar 27;89(6):764-5. doi: 10.1097/TP.0b013e3181c9025d. No abstract available.


Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.

Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK.

J Clin Oncol. 2010 Apr 20;28(12):2032-7. doi: 10.1200/JCO.2009.24.6314. Epub 2010 Mar 22.


MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B.

Neuro Oncol. 2010 Aug;12(8):822-33. doi: 10.1093/neuonc/noq017. Epub 2010 Feb 23.


Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.

Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B.

Cancer Res. 2009 Nov 15;69(22):8620-8. doi: 10.1158/0008-5472.CAN-09-1591. Epub 2009 Nov 3.


Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Quon H, Hasbini A, Cougnard J, Djafari L, Lacroix C, Abdulkarim B.

J Neurooncol. 2010 Jan;96(2):277-85. doi: 10.1007/s11060-009-9961-x. Epub 2009 Jul 19.


Supplemental Content

Loading ...
Support Center